Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
Status:
Recruiting
Trial end date:
2024-11-26
Target enrollment:
Participant gender:
Summary
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics
(PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with
Hereditary Angioedema (HAE).